SCHEMBL27021671

SCHEMBL27021671

CC(C)c1cccnc1C(=O)NS(=O)(=O)C1CC1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 3/20 0.39
SCN2B O60939 1/20 0.39
SCN1B Q07699 1/20 0.39
CHRNA7 P36544 1/20 0.37
BACE1 P56817 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
MRGPRX1 Q96LB2 2/20 0.35
CKS1B P61024 2/20 0.35
SKP2 Q13309 2/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CTPS1 P17812 1/20 0.35
SCN5A Q14524 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27021659 0.82 L3MBTL1 (0.41) ALDH1A1LMNASMN1; SMN2
SCHEMBL26898660 0.81 ALDH1A1 (0.40) CHRNA7BACE1TDP1ALDH1A1GAA
SCHEMBL18798786 0.79 MRGPRX1 (0.46) SCN9AALDH1A1MRGPRX1LMNASCN5A
SCHEMBL26898635 0.78 BACE1 (0.38) BACE1ALDH1A1LMNASMN1; SMN2
SCHEMBL26856720 0.78 KDM4E (0.50) ALDH1A1KDM4EGAA
SCHEMBL26856985 0.77 TLR7 (0.39) BACE1ALDH1A1LMNASMN1; SMN2
SCHEMBL26898659 0.77 SCN9A (0.40) SCN9AALDH1A1KDM4EGAALMNA
SCHEMBL26856992 0.77 GAA (0.40) ALDH1A1KDM4EGAA
SCHEMBL26898604 0.76 ALDH1A1 (0.58) ALDH1A1KDM4EGAASMN1; SMN2
SCHEMBL26874929 0.75 CTSA (0.37) BACE1ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018115-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE LOXO ONCOLOGY, INC. 2024-01-18 US disclosed
US-20240018115-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE LOXO ONCOLOGY, INC. 2024-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018115-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, PIK3R4, PIK3R5 SCN9A 2496/4885SCN2B 1761/4885SCN1B 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.